Business Description
Ever Supreme Bio Technology Co Ltd
ISIN : TW0006712003
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 112.08 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 2985.46 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 29.68 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 113.6 | |||||
3-Year Book Growth Rate | 29.7 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 79.19 | |||||
9-Day RSI | 62.93 | |||||
14-Day RSI | 55.1 | |||||
6-1 Month Momentum % | -9.61 | |||||
12-1 Month Momentum % | -1.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.31 | |||||
Quick Ratio | 2.92 | |||||
Cash Ratio | 2.32 | |||||
Days Inventory | 129.63 | |||||
Days Sales Outstanding | 45.03 | |||||
Days Payable | 34.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.39 | |||||
Dividend Payout Ratio | 1.91 | |||||
Forward Dividend Yield % | 3.39 | |||||
5-Year Yield-on-Cost % | 3.39 | |||||
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | 3.5 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.01 | |||||
Operating Margin % | 50.18 | |||||
Net Margin % | 30.1 | |||||
FCF Margin % | 49.19 | |||||
ROE % | 14.83 | |||||
ROA % | 12.93 | |||||
ROIC % | 36.61 | |||||
ROC (Joel Greenblatt) % | 488.13 | |||||
ROCE % | 19.35 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 56.27 | |||||
Forward PE Ratio | 28.98 | |||||
PE Ratio without NRI | 56.2 | |||||
Price-to-Owner-Earnings | 52.02 | |||||
PS Ratio | 16.93 | |||||
PB Ratio | 9 | |||||
Price-to-Tangible-Book | 9.09 | |||||
Price-to-Free-Cash-Flow | 34.49 | |||||
Price-to-Operating-Cash-Flow | 34.39 | |||||
EV-to-EBIT | 40.74 | |||||
EV-to-EBITDA | 37.33 | |||||
EV-to-Revenue | 16.16 | |||||
EV-to-FCF | 32.25 | |||||
Price-to-Projected-FCF | 5.45 | |||||
Price-to-Graham-Number | 4.77 | |||||
Price-to-Net-Current-Asset-Value | 23.35 | |||||
Price-to-Net-Cash | 42.14 | |||||
Earnings Yield (Greenblatt) % | 2.45 | |||||
FCF Yield % | 2.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ever Supreme Bio Technology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 844.861 | ||
EPS (TTM) (NT$) | 3.137 | ||
Beta | 0.42 | ||
Volatility % | 16.52 | ||
14-Day RSI | 55.1 | ||
14-Day ATR (NT$) | 2.544481 | ||
20-Day SMA (NT$) | 175.575 | ||
12-1 Month Momentum % | -1.59 | ||
52-Week Range (NT$) | 166 - 215 | ||
Shares Outstanding (Mil) | 80.67 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ever Supreme Bio Technology Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ever Supreme Bio Technology Co Ltd Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
Ever Supreme Bio Technology Co Ltd Frequently Asked Questions
What is Ever Supreme Bio Technology Co Ltd(ROCO:6712)'s stock price today?
When is next earnings date of Ever Supreme Bio Technology Co Ltd(ROCO:6712)?
Does Ever Supreme Bio Technology Co Ltd(ROCO:6712) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |